open access

Vol 21, No 4 (2015)
Original papers
Published online: 2016-06-23
Get Citation

Endovascular treatment of femoro-popliteal artery stenosis/obstruction using a repositionable self-expanding nitinol stent: a preliminary study

Seyhan Yılmaz, Behice Kaniye Yılmaz, Özgür Barış, Orhan Fındık, Mehmet Kalender, Eray Aksoy
DOI: 10.5603/AA.2015.0020
·
Acta Angiologica 2015;21(4):116-121.

open access

Vol 21, No 4 (2015)
Original papers
Published online: 2016-06-23

Abstract

Introduction. The aim of this study was to report our preliminary results regarding the use of the repositionable self-expanding nitinol stent in a cohort of patients with femoro-popliteal artery occlusion/stenosis.

Material and methods. The study groups consisted a total of 8 patients (10 extremities) between 47 and 70 years of age who presented with typical symptoms of intermittent claudication and/or critical limb ischaemia (Fontaine stage II–IV) and underwent primary elective superficial femoral artery percutaneous transluminal angioplasty and/or stenting using a Jaguar repositionable self-expanding nitinol stent in the dates of 2013–2015. Information for patency at 6th month after the stenting procedure was obtained.

Results. The mean operation time was 38.56 ± 26.40 minutes. No patients had procedure-related stent fracture, distal thromboembolism, haematoma, femoral pseudoaneurysm or stent occlusion. At 6-month follow-up, at least one categorical improvement was observed in 7 patients (87.5% of intent-to-treat population).

Conclusions. The Jaguar self-expanding nitinol stent has several technical advantages, and its use was associated with a low risk of complications. Further study is warranted to establish its superiority in providing good long-term patency.

Abstract

Introduction. The aim of this study was to report our preliminary results regarding the use of the repositionable self-expanding nitinol stent in a cohort of patients with femoro-popliteal artery occlusion/stenosis.

Material and methods. The study groups consisted a total of 8 patients (10 extremities) between 47 and 70 years of age who presented with typical symptoms of intermittent claudication and/or critical limb ischaemia (Fontaine stage II–IV) and underwent primary elective superficial femoral artery percutaneous transluminal angioplasty and/or stenting using a Jaguar repositionable self-expanding nitinol stent in the dates of 2013–2015. Information for patency at 6th month after the stenting procedure was obtained.

Results. The mean operation time was 38.56 ± 26.40 minutes. No patients had procedure-related stent fracture, distal thromboembolism, haematoma, femoral pseudoaneurysm or stent occlusion. At 6-month follow-up, at least one categorical improvement was observed in 7 patients (87.5% of intent-to-treat population).

Conclusions. The Jaguar self-expanding nitinol stent has several technical advantages, and its use was associated with a low risk of complications. Further study is warranted to establish its superiority in providing good long-term patency.

Get Citation

Keywords

peripheral obstructive disease, angioplasty, critical limb ischaemia

About this article
Title

Endovascular treatment of femoro-popliteal artery stenosis/obstruction using a repositionable self-expanding nitinol stent: a preliminary study

Journal

Acta Angiologica

Issue

Vol 21, No 4 (2015)

Pages

116-121

Published online

2016-06-23

DOI

10.5603/AA.2015.0020

Bibliographic record

Acta Angiologica 2015;21(4):116-121.

Keywords

peripheral obstructive disease
angioplasty
critical limb ischaemia

Authors

Seyhan Yılmaz
Behice Kaniye Yılmaz
Özgür Barış
Orhan Fındık
Mehmet Kalender
Eray Aksoy

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail: viamedica@viamedica.pl